Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Total Debt (2021 - 2026)

bioAffinity Technologies has reported Total Debt over the past 6 years, most recently at $38915.0 for Q1 2026.

  • Quarterly Total Debt fell 19.19% to $38915.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $38915.0 through Mar 2026, down 19.19% year-over-year, with the annual reading at $41313.0 for FY2025, 104.72% up from the prior year.
  • Total Debt was $38915.0 for Q1 2026 at bioAffinity Technologies, down from $41313.0 in the prior quarter.
  • Over five years, Total Debt peaked at $500000.0 in Q3 2022 and troughed at $20180.0 in Q4 2024.
  • The 5-year median for Total Debt is $42334.0 (2023), against an average of $97551.2.
  • Year-over-year, Total Debt plummeted 86.32% in 2024 and then skyrocketed 109.04% in 2025.
  • A 5-year view of Total Debt shows it stood at $251746.0 in 2022, then plummeted by 83.18% to $42334.0 in 2023, then tumbled by 52.33% to $20180.0 in 2024, then skyrocketed by 104.72% to $41313.0 in 2025, then dropped by 5.8% to $38915.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Total Debt are $38915.0 (Q1 2026), $41313.0 (Q4 2025), and $43658.0 (Q3 2025).